| Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer … T Crombet, M Osorio, T Cruz, C Roca, R del Castillo, R Mon, ... Journal of Clinical Oncology 22 (9), 1646-1654, 2004 | 402 | 2004 |
| Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial T Crombet Ramos, J Figueredo, M Catala, G Sandra, JC Selva, TM Cruz, ... Cancer biology & therapy 5 (4), 375-379, 2006 | 214 | 2006 |
| Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation … M Ramos-Suzarte, P Lorenzo-Luaces, NG Lazo, ML Perez, JL Soriano, ... Cancer biology & therapy 13 (8), 600-605, 2012 | 100 | 2012 |
| Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188-Re in adult recurrent high-grade glioma A Casacó, G López, I García, J Arsenio Rodríguez, R Fernández, ... Cancer biology & therapy 7 (3), 333-339, 2008 | 95 | 2008 |
| 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy M Ramos-Suzarte, N Rodriguez, JP Oliva, N Iznaga-Escobar, A Perera, ... Journal of Nuclear Medicine 40 (5), 768-775, 1999 | 82 | 1999 |
| Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study T Crombet, O Torres, V Rodriguez, A Menendez, A Stevenson, M Ramos, ... Hybridoma 20 (2), 131-136, 2001 | 79 | 2001 |
| A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis PC Rodriguez, R Torres-Moya, G Reyes, C Molinero, D Prada, AM Lopez, ... Results in immunology 2, 204-211, 2012 | 73 | 2012 |
| Nimotuzumab: beyond the EGFR signaling cascade inhibition Z Mazorra, L Chao, A Lavastida, B Sanchez, M Ramos, N Iznaga, ... Seminars in oncology 45 (1-2), 18-26, 2018 | 62 | 2018 |
| Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin LA Torres, A Perera, JF Batista, A Hernández, T Crombet, M Ramos, ... Nuclear medicine communications 26 (12), 1049-1057, 2005 | 48 | 2005 |
| Systemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti-epidermal growth factor receptor … ME Arteaga, N Nuris Ledon, A Casacó, B Pardo, M García, M Boleda, ... Cancer biology & therapy 6 (9), 1386-1391, 2007 | 44 | 2007 |
| Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor T Crombet, O Torres, E Neninger, M Catalá, N Rodríguez, M Ramos, ... Cancer Biotherapy and Radiopharmaceuticals 16 (1), 93-102, 2001 | 39 | 2001 |
| Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19 Y Díaz, M Ramos-Suzarte, Y Martín, NA Calderón, W Santiago, O Viñet, ... Gerontology 66 (6), 553-561, 2020 | 37 | 2020 |
| A phase I study of 99mTc-hR3 (DiaCIM®), a humanized immunoconjugate directed towards the epidermal growth factor receptor KA Vallis, RM Reilly, P Chen, A Oza, A Hendler, R Cameron, M Hershkop, ... Nuclear medicine communications 23 (12), 1155-1164, 2002 | 37 | 2002 |
| A pilot study of nimotuzumab plus single agent chemotherapy as second-or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer L Cetina, T Crombet, R Jiménez-Lima, S Zapata, M Ramos, S Avila, ... Cancer biology & therapy 16 (5), 684-689, 2015 | 36 | 2015 |
| Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy N Iznaga-Escobar, LA Torres, A Morales, M Ramos The Journal of Nuclear Medicine 39 (1), 15, 1998 | 34 | 1998 |
| An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients D Saavedra, AL Añé-Kourí, N Sánchez, LM Filgueira, J Betancourt, ... Immunity & Ageing 17, 1-8, 2020 | 33 | 2020 |
| Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience S Xu, M Ramos-Suzarte, X Bai, B Xu Oncotarget 7 (22), 33391, 2016 | 30 | 2016 |
| Pharmacokinetics, biodistribution and dosimetry of 99mTc-labeled anti-human epidermal growth factor receptor humanized monoclonal antibody R3 in rats NI Escobar, AM Morales, J Ducongé, IC Torres, E Fernández, JA Gómez Nuclear medicine and biology 25 (1), 17-23, 1998 | 30 | 1998 |
| Oncogenomics and Cancer Proteomics: Novel Approaches in Biomarkers Discovery and Therapeutic Targets in Cancer C López-Camarillo, E Aréchaga-Ocampo BoD–Books on Demand, 2013 | 25 | 2013 |
| Biodistribution of 99mTc-labeled anti-human epidermal growth factor receptor (EGF-R) humanized monoclonal antibody h-R3 in a xenograft model of human lung adenocarcinoma A Morales-Morales, J Ducongé, I Caballero-Torres, G Núñez-Gandolff, ... Nuclear medicine and biology 26 (3), 275-279, 1999 | 23 | 1999 |
Tania Crombet Ramos, MD, PhDClinical Research Director, Center of Molecular Immunology, Havana, CubaVerified email at cim.sld.cu
